ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Silvr, my take away is the following:

- Novitium likely gets first dibs on the 100+ drug submission Scitus roles out by the end of the year. It likely secures ANIP's long term growth of their generic pillar.
- Nuray Chemicals also has the patent for an improved Tafamidis. This will take some clinical trial work to get it approved once the Pfizer patent expires in 2026.

Given how expensive it has become to borrow, Samy may be using the proceeds from the shares he(or his companies) sold to fund their activities. If so, it is a win- win-win for him. It should grow the value of all three companies.

As for female testosterone, I would not be surprised to see a new private company formed with a partnership between ANIP, AbbVie and another big pharma (possibly Merck) built around female testosterone. I figure a multi company partnership is the reason it has not yet been announced. If only AbbVie were involved, I believe it would have already been announced by now.

JMHO.